The elevation of serum creatine kinase in the course of Parkinson disease. - In relation to malignant syndrome

Clinical Neurology

Volumn 36, Issue 8, 1996, Pages 935-939

  Shimoda Matsubayashi, Satoe ^a   Yagi, Kouichi ^b   Tanabe, Hitoshi ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

Author keywords

Creatine kinase; Malignant syndrome; Parkinson disease

Indexed keywords

ANTIPARKINSON AGENT; CREATINE KINASE; DOPAMINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DEMENTIA; DOPAMINE RELEASE; FEMALE; FEVER; GENDER; HALLUCINATION; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE;

AGED; CREATINE KINASE; DEMENTIA; FEMALE; HUMANS; MALE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 0029852146     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Delay J, Pichot P, Lempértère MT, et al: Un neuroleptique majeur non phénothiazinique et non réserpinique, l'halopéridol, dans le traitement des psychoses. Ann Méd-Psych 118: 145-152, 1960
2. Toru M, Matsuda O, Makiguchi K, et al: Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169: 324-327, 1981
3. Calne DB, Snow BJ, Lee C: Criteria for diagnosing Parkinson's disease. Ann Neurol 32: S125- S127, 1992
4. Levenson JL: Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137-1145, 1985
5. Henderson VW, Wooten GF: Neuroleptic malignant syndrome : a pathogenetic role for dopamine receptor blockade? Neurology 31: 132-137, 1981
6. Lew T-Y, Tollefson G: Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 18: 1441-1446, 1983
7. Feibel JH, Schiffer RB: Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report. Am J Psychiatry 138: 1115-1116, 1981